Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

2

Revenue 2017

Revlimid

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Revlimid was produced by Celgene.

NICE partially clears Darzalex combo in blood cancer

NICE partially clears Darzalex combo in blood cancer

Notably, 29% of those in one trial arm used Celgene’s Revlimid as their first-line treatment; where as only 12% in the other group used Darzalex. ... Clinical experts stated that there was no evidence to suggest that Revlimid modifies the effect of

FDA begins speedy review of Celgene’s Revlimid combo in lymphoma

FDA begins speedy review of Celgene’s Revlimid combo in lymphoma It also met the secondary endpoint of overall survival, with only 16 death events reported in the Revlimid combo group versus 26 death events in the comparator arm. ... It's one of five new drugs that Celgene aims to launch through 2020, and the company

Sanofi's Darzalex rival scores in myeloma trial

Sanofi's Darzalex rival scores in myeloma trial Celgene’s Revlimid (lenalidomide) and dexamethasone.

BMS isn’t phased by Opdivo’s slowing growth – for now

BMS isn’t phased by Opdivo’s slowing growth – for now over Celgene’s top-seller Revlimid (lenalidomide), which accounts for almost two-thirds of its sales but is facing the threat of generic competition in the coming years.

BMS and Celgene deal sparks debate on pharma profit motive, more M&A

BMS and Celgene deal sparks debate on pharma profit motive, more M&A However there were also those pointing to what many see as Celgene’s abuse of patents and US regulations to protect Revlimid, its top-selling myeloma treatment, which earned over $8bn ... These rows have generated uncertainty about when Revlimid will

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...

Infographics